Pharmacokinetic Software
6 software items found
by:Certara based inPrinceton, NEW JERSEY (USA)
The one software ecosystem to streamline your PK/PD data management and analysis; With all the tools you need in a single, interoperable platform, effortlessly share pre-clinical and clinical knowledge across your organization through secure and consistent workflows using Phoenix-based tools and 3rd-party applications. Phoenix WinNonlin is the first choice for non-compartmental analysis (NCA), ...
by:Certara based inPrinceton, NEW JERSEY (USA)
Phoenix WinNonlin is used by over 10,000 scientists at more than 1,500 establishments in 60 countries. It is the industry standard for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and toxicokinetic (TK) modeling with a proven 30-year history. Regulatory agencies, including the US FDA, Japan Pharmaceutical and Medical Device Agency (PMDA), China Food ...
by:Simulations Plus based inLancaster, CALIFORNIA (USA)
GastroPlus is a simulation software designed for detailed mechanistic modeling of drug absorption across various administration routes including intravenous, oral, ocular, inhalation, dermal, subcutaneous, and intramuscular delivery. It is utilized to simulate the pharmacokinetics and pharmacodynamics properties in both humans and animals. The platform integrates user-friendly ...
by:Simulations Plus based inLancaster, CALIFORNIA (USA)
Its proprietary modules support the creation of QSAR/QSPR models and facilitate advanced data mining techniques. By utilizing ADMET Predictor, one can streamline the assessment of pharmacokinetic risks such as high plasma protein binding and volume of distribution, contributing to safer and more effective drug development ...
by:Certara based inPrinceton, NEW JERSEY (USA)
The Simcyp Simulator is the pharmaceutical industry’s most sophisticated physiologically based pharmacokinetics (PBPK) platform for determining first-in-human dosing, optimizing clinical study design, evaluating new drug formulations, setting the dose in untested populations, performing virtual bioequivalence analyses, and predicting drug-drug interactions (DDIs). ...
by:Certara based inPrinceton, NEW JERSEY (USA)
Due to this high affinity, the binding to the target and subsequent turnover of the drug–target complex can contribute significantly to the disposition of biologics. The pharmacokinetic (PK) properties of biologics are quite distinct from that of small molecules, as are the interactions with targets ...